CA2832059C - Inflammation and immunity treatments - Google Patents

Inflammation and immunity treatments Download PDF

Info

Publication number
CA2832059C
CA2832059C CA2832059A CA2832059A CA2832059C CA 2832059 C CA2832059 C CA 2832059C CA 2832059 A CA2832059 A CA 2832059A CA 2832059 A CA2832059 A CA 2832059A CA 2832059 C CA2832059 C CA 2832059C
Authority
CA
Canada
Prior art keywords
composition
subject
flavonols
proanthocyanidins
ratio
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2832059A
Other languages
English (en)
French (fr)
Other versions
CA2832059A1 (en
Inventor
Christina Khoo
Deann Liska
Susan S. Percival
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ocean Spray Cranberries Inc
Original Assignee
Ocean Spray Cranberries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ocean Spray Cranberries Inc filed Critical Ocean Spray Cranberries Inc
Publication of CA2832059A1 publication Critical patent/CA2832059A1/en
Application granted granted Critical
Publication of CA2832059C publication Critical patent/CA2832059C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2832059A 2011-04-01 2012-03-30 Inflammation and immunity treatments Active CA2832059C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161471073P 2011-04-01 2011-04-01
US61/471,073 2011-04-01
PCT/US2012/031581 WO2012135702A1 (en) 2011-04-01 2012-03-30 Inflammation and immunity treatments

Publications (2)

Publication Number Publication Date
CA2832059A1 CA2832059A1 (en) 2012-10-04
CA2832059C true CA2832059C (en) 2020-07-14

Family

ID=46931951

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2832059A Active CA2832059C (en) 2011-04-01 2012-03-30 Inflammation and immunity treatments

Country Status (4)

Country Link
US (1) US9895341B2 (enExample)
JP (1) JP2014509656A (enExample)
CA (1) CA2832059C (enExample)
WO (1) WO2012135702A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20130476A1 (it) * 2013-03-28 2014-09-29 Novintethical Pharma Sagl Composizioni per il trattamento di disturbi gastro-intestinali a base di complessi di tannini con proteine
US10034704B2 (en) 2015-06-30 2018-07-31 Ethicon Llc Surgical instrument with user adaptable algorithms
JOP20190276A1 (ar) * 2017-05-31 2019-11-27 Napo Pharmaceuticals Inc طرق وتركيبات لعلاج إسهال الحمض الصفراوي، والإسهال المرتبط باستئصال الأمعاء الدقيقة أو إزالة المرارة، ومتلازمة الأمعاء القصيرة

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69739394D1 (de) 1996-10-16 2009-06-18 Napo Pharmaceuticals Inc Enteral-formulierungen von proanthocyanidzusammensetzungen gegen diarrhöe
JP2975997B2 (ja) * 1998-03-04 1999-11-10 工業技術院長 プロアントシアニジンａおよびその誘導体
US20020054924A1 (en) * 2000-04-13 2002-05-09 Leahy Margaret M. Novel compositions derived from cranberry and grapefruit and therapeutic uses therefor
US7306815B2 (en) 2000-08-31 2007-12-11 Phenolics, Llc Compositions enriched in phenolic compounds and methods for producing the same
WO2005030200A1 (ja) 2003-09-26 2005-04-07 Kirin Beer Kabushiki Kaisha 自己免疫疾患治療剤
JP5167461B2 (ja) 2005-09-16 2013-03-21 国立医薬品食品衛生研究所長 炎症性腸疾患予防剤
US20070254050A1 (en) 2006-05-01 2007-11-01 Quart Barry D Method for treatment of diarrhea-predominant irritable bowel syndrome
WO2008004224A2 (en) * 2006-07-03 2008-01-10 Arie Levine Synergistic compositions for crohn's disease and inflammatory gastrointestinal disorders
US20090226548A1 (en) * 2008-01-11 2009-09-10 U.S. Nutraceuticals, Llc D/B/A Valensa International Method of preventing, controlling and ameliorating urinary tract infections using a synergistic cranberry derivative and d-mannose composition
JP5462491B2 (ja) 2009-01-21 2014-04-02 株式会社 エフェクト プロアントシアニジン三量体
WO2010121203A1 (en) 2009-04-16 2010-10-21 Ocean Spray Cranberries, Inc. Phenolics extraction and use
WO2011088420A1 (en) * 2010-01-15 2011-07-21 Ocean Spray Cranberries, Inc. Process for extracting compound from cranberry leaves and related products
US9314494B2 (en) * 2012-05-25 2016-04-19 The United States Of America, As Represented By The Secretary Of Agriculture Cranberry xyloglucan oligosaccharide composition

Also Published As

Publication number Publication date
CA2832059A1 (en) 2012-10-04
US9895341B2 (en) 2018-02-20
WO2012135702A1 (en) 2012-10-04
US20140134206A1 (en) 2014-05-15
JP2014509656A (ja) 2014-04-21

Similar Documents

Publication Publication Date Title
Peng et al. Gut microbiota modulation and anti-inflammatory properties of anthocyanins from the fruits of Lycium ruthenicum Murray in dextran sodium sulfate-induced colitis in mice
CN108541221B (zh) Hmo的混合物
JP2023010890A (ja) 潰瘍性大腸炎を治療するための方法
Wang et al. Prevention of Cyclophosphamide‐Induced Immunosuppression in Mice with the Antimicrobial Peptide Sublancin
Kim et al. Lactobacillus plantarum CBT LP3 ameliorates colitis via modulating T cells in mice
JP7011885B2 (ja) 腸の健康を促す組成物
Gallotti et al. Effects of dietary fibre intake in chemotherapy-induced mucositis in murine model
HUE034628T2 (hu) Emberi és/vagy állati élelmiszer készítmény, ennek alkalmazásai, élesztõk
Ran et al. Preventive effect of Chinese dwarf cherry [Cerasus humilis (Bge.) Sok.] fermentation juice on dextran sulfate sodium-induced ulcerative colitis rats through the regulation of IgA and the intestinal immune barrier
JP2021519763A (ja) 炎症性腸疾患を治療するための組成物及び方法
CA2832059C (en) Inflammation and immunity treatments
Zhou et al. Miao sour soup influences serum lipid via regulation of high‐fat diet‐induced intestinal flora in obese rats
Wang et al. Rutin, a natural flavonoid glycoside, ameliorates zearalenone induced liver inflammation via inhibiting lipopolysaccharide gut leakage and NF-κB signaling pathway in mice
Mao et al. Quercetin increases growth performance and decreases incidence of diarrhea and mechanism of action in weaned piglets
US12213506B2 (en) Compositions and methods to counteract processes associated with inflammation and senescence and to support cellular energy and/or metabolism
CN107073032A (zh) 肾衰竭发展抑制剂、肾衰竭预防剂及硫酸吲哚酚产生抑制剂
WO2022265151A1 (ko) 비피도박테리움 비피덤 bgn4를 함유한 신부전 개선용, 치료용 또는 예방용 조성물
Meng et al. Saikosaponin inhibits Eimeria tenella infection by modifying the NF-κB pathway and regulating cytokines and the intestinal microbial community
CN110870877A (zh) 戈氏副拟杆菌用于制备治疗慢性肾脏疾病的医药组合物的用途
Patankar et al. A prospective, randomized, open label, parallel group, comparative clinical trial to evaluate the safety and efficacy of combination of herbal oral capsule and rectal medication to improve gut health of type 2 diabetic patients having chronic kidney disease (CKD)
TWI837825B (zh) 以普通擬桿菌治療大腸癌和/或發炎疾病之方法
JP7601332B2 (ja) 便秘解消組成物
Wu et al. EGCG ameliorates DSS-induced colitis potentially via suppressing GPR43-mediated Th1 polarization
Shan et al. Pretreatment with Astragalus polysaccharide alleviates heat stroke–induced intestinal injury in mice
US20250268971A1 (en) Saffron as anti-inflammatory agent in treating inflammatory bowel disease

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170328